Icatibant

Icatibant, the active ingredient in Icatibant, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed diagnosis, providing rapid relief of swelling and associated pain.

GNH USA supplies Icatibant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company maintains cold‑chain logistics for injectable products and provides documentation to meet local import requirements.

Icatibant is used to treat hereditary angioedema, a bradykinin‑mediated swelling disorder.

- Hereditary angioedema acute attacks: provides rapid reduction of swelling and pain during an attack. - Hereditary angioedema type I attacks: shortens the duration of edema episodes. - Hereditary angioedema type II attacks: alleviates symptoms and improves patient comfort.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema or edema. - Headache: transient headache occurring shortly after dosing. - Nausea: occasional feeling of nausea without vomiting.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis requiring medical attention. - Severe abdominal pain: persistent abdominal discomfort that may need evaluation. - Thrombocytopenia: rare decrease in platelet count observed in some patients. - Angioedema unrelated to HAE: rare swelling of face or throat not caused by hereditary angioedema.

When prescribing Icatibant, clinicians should consider several safety and handling precautions. - Confirm diagnosis: verify hereditary angioedema before initiating therapy. - Monitor for hypersensitivity: observe patients for rash, urticaria, or anaphylactic signs after injection. - Assess cardiovascular status: bradykinin blockade may affect blood pressure in susceptible individuals. - Use with caution in pregnancy: safety data are limited; weigh potential benefits against unknown risks. - Observe renal/hepatic function: no dose adjustment required, but clinical response should be monitored in impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or affect injection site reactions.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - DPP‑4 inhibitors: potential additive effect on bradykinin metabolism. - Other B2 receptor antagonists: concurrent use may lead to excessive blockade.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of localized injection site inflammation. - Antihistamines: can mask early signs of hypersensitivity reactions. - Corticosteroids: may alter immune response, requiring observation for infection or delayed healing.